At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...